

**Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up**

<b>Rs. Mio.</b>	<b>Q1 16-17</b>	<b>Q1 15-16</b>	<b>% Gr y-y</b>
<b>Formulations Business - Key Markets</b>	<b>18,208</b>	<b>19,053</b>	<b>-4.4%</b>
US Formulations	8,483	9,850	-13.9%
India Formulations	7,862	7,404	6.2%
Latin America Formulations	527	553	-4.7%
Emerging Markets Formulations	1,336	1,246	7.3%
<b>Other Businesses and Alliances</b>	<b>4,416</b>	<b>4,053</b>	<b>8.9%</b>
Europe Formulations	792	836	-5.3%
Consumer Wellness	1,161	1,035	12.2%
Animal Health & Others	1,097	763	43.8%
APIs	976	980	-0.4%
Alliances	390	440	-11.3%
<b>Grand Total</b>	<b>22,624</b>	<b>23,106</b>	<b>-2.1%</b>

**Cadila Healthcare Ltd.**

**Details of other incomes**

Rs. Mio.	Q1 16-17	Q1 15-16	% Gr y-y
<b>Other Operating Income</b>	<b>707</b>	<b>1,155</b>	<b>-38.8%</b>
Export Incentive	287	226	26.8%
Royalty Income	30	39	-22.3%
Net Gain on foreign currency transactions and translation (Refer Note below)	231	63	269.3%
Others	159	827	-80.8%

Note : There was a net gain of Rs. 237 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q1 16-17. Thus, on aggregate level, there was a gain of Rs. 468 Mio. on operating transactions (above EBIDTA line) in Q1 16-17 vs gain of Rs. 195 Mio. in Q1 15-16. See details below for more clarity.

Rs. Mio.	Q1 16-17	Q1 15-16	% Gr y-y
<b>Other Income</b>	<b>153</b>	<b>240</b>	<b>-36.4%</b>
Interest & Dividend income	121	143	-15.8%
Profit on sale of investments	31	33	-3.5%
Others	1	65	-98.7%

**Details of Foreign Exchange Fluctuations**

Rs. Mio. (+ = loss, - = gain)	Q1 16-17	Q1 15-16	% Gr y-y
<b>A. On operating transactions (above EBIDTA line)</b>	<b>-468</b>	<b>-195</b>	<b>-140.0%</b>
a. Included in other income	-231	-63	-266.7%
b. Included in cost of goods	-237	-132	-79.5%
<b>B. On Foreign Currency Borrowings (part of interest cost)</b>	<b>18</b>	<b>5</b>	<b>260.0%</b>
<b>Total Foreign Currency Fluctuations (+ = loss, - = gain)</b>	<b>-450</b>	<b>-190</b>	<b>-136.8%</b>

**Details of R&D Expenses**

Rs. Mio.	Q1 16-17	Q1 15-16	% Gr y-y
<b>Total R&amp;D Expenses</b>	<b>1,626</b>	<b>1,684</b>	<b>-3.4%</b>

Consolidated Capex for Q1 FY17

**Rs. 2968  
Mio.**

R&D capex included in above for Q1 FY17

**Rs. 65  
Mio.**